Investigational drug · Phase 3
TQB2102
Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
11
11 still active
All registered trials
18
Any phase or sponsor naming "TQB2102"
First trial start
2024
Jul 22, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB2102", any sponsor or status.
- Phase 211
Conditions studied
As listed on its trial records.
- Breast Cancer
- HER2-positive Breast Cancer
- Gynecological Tumors
- HER2 IHC3+ Advanced Colorectal Cancer
- Non-Small Cell Lung Cancer
- Advanced Solid Tumor
- Metastatic Breast Cancer
- Gastroesophageal Adenocarcinoma
- Biliary Tract Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB2102" as an intervention, largest first.
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07003074 · 642 participants (planned) · Start Jun 23, 2025 · Primary completion Jul 2029
Drug: TQB2102 for Injection; Docetaxel combined + Trastuzumab +Pertuzumab · For: Breast Cancer
Sites: Hefei, China; Beijing, China; Lanzhou, China · 25 sites in all
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07043725 · 544 participants (planned) · Start Sep 15, 2025 · Primary completion Sep 2027
Drug: TQB2102 for injection; Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection · For: HER2-positive Breast Cancer
Sites: Bengbu, China; Hefei, China; Wuhu, China · 77 sites in all
- A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast CancerPivotal-lookingActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06561607 · 542 participants (planned) · Start Oct 11, 2024 · Primary completion Jan 2027
Drug: TQB2102 for Injection; Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) · For: Breast Cancer
Sites: Bengbu, China; Hefei, China; Beijing, China · 34 sites in all
- Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.Pivotal-lookingNot yet recruiting
Henan Cancer HospitalGovernment (non-federal)
NCT07136974 · 280 participants (planned) · Start Sep 1, 2025 · Primary completion Aug 30, 2028
Drug: TQB2102; Docetaxel + Carboplatin + Trastuzumab +Pertuzumab · For: Breast Cancer; HER2 + Breast Cancer
Sites: Zhengzhou, China
- A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene AbnormalityRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06496490 · 270 participants (planned) · Start Aug 6, 2024 · Primary completion Jun 2026
Drug: TQB2102 for injection; TQB2102 for injection combined with Benmelstobart injection · For: Non-Small Cell Lung Cancer
Sites: Fuzhou, China; Foshan, China; Guangzhou, China · 25 sites in all
- Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast CancerPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07008976 · 246 participants (planned) · Start Jul 7, 2025 · Primary completion Mar 2028
Drug: TQB2102 Injection; Trastuzumab Emtansine for Injection · For: Metastatic Breast Cancer
Sites: Bengbu, China; Hefei, China; Beijing, China · 31 sites in all
- Clinical Trial of the TQB2102 Injection in Patients With Advanced CancersActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT05735496 · 219 participants · Start Mar 9, 2023 · Primary completion Jul 21, 2025
Drug: TQB2102 injection · For: Advanced Cancer
Sites: Fuzhou, China; Guangzhou, China; Harbin, China · 12 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06767800 · 204 participants (planned) · Start Nov 21, 2024 · Primary completion Sep 2026
Drug: TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy; TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy and 1 more · For: Gastroesophageal Adenocarcinoma
Sites: Fuyang, China; Lu'an, China; Maanshan, China · 39 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07512583 · 178 participants (planned) · Start May 27, 2026 · Primary completion Mar 2028
Drug: TQB2930 injection+TQB2102 for injection · For: Advanced Solid Tumor
Sites: Beijing, China; Harbin, China; Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
- From Dual Targeting to Clinical Validation: A Translational Framework for Bispecific Antibody-Drug Conjugates.
Kim J, Kang S · Int J Mol Sci 2026
- Preclinical characterization and phase I results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors.
Ruan DY, Lin SY, Huang JJ, et al. · Ann Oncol 2026
- Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial.
Li JJ, Zhang WJ, Zeng XH, et al. · J Clin Oncol 2026
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- JSKN003Phase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Colorectal Cancer, Advanced Solid Tumor, HER2-positive Gastric Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.